{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:21Z","timestamp":1792788681967,"version":"4.5.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Center for Advancing Translational Sciences","award":["KL2TR002317"],"award-info":[{"award-number":["KL2TR002317"]}],"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","award":["P30 DK035816"],"award-info":[{"award-number":["P30 DK035816"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Sphingolipids with long fatty acids (16\u201318 carbons) were associated with all-cause and cardiovascular death in patients treated with hemodialysis.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Sphingolipids with very-long fatty acids (20+ carbons) were associated with lower risk of all-cause and cardiovascular death in dialysis patients.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with kidney failure on hemodialysis are at a higher risk for death, especially cardiovascular death. Statins (which improve outcomes in general populations) do not improve outcomes in dialysis patients. Sphingolipids are mechanistically associated with cardiovascular disease and may represent novel, modifiable risk factors for death in patients with kidney failure. We aimed to examine the associations of sphingolipids with death specifically in dialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Hemodialysis (HEMO) Study (a multicenter factorial trial of dose and flux), we measured 16 sphingolipids (ceramides-16:0, 18:0, 20:0, 22:0, 24:0, and 24:1; hexosylceramides-16:0, 22:0, and 24:0; lactosylceramide-16:0; and sphingomyelins 14:0, 16:0, 18:0, 20:0, 22:0, and 24:0) at baseline only in 927 participants with available stored serum using targeted liquid chromatography\u2013tandem mass spectrometry. The primary outcome was all-cause death, with physician-adjudicated cause (cardiovascular versus noncardiovascular) as a secondary outcome. We examined the associations of sphingolipids with death using Cox regressions, controlling the false discovery rate &lt;5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 927 participants, the mean (SD) age was 57 (14) years; median (interquartile range) dialysis vintage was 1.9 (0.8\u20134.1) years. Over a median (interquartile range) follow-up of 2.4 (1.4\u20134.0) years, there were 376 deaths. Nine of 16 sphingolipids were significantly associated with death, including ceramide-16:0 (adjusted hazard ratio [aHR] 2.13 per two-fold higher concentration, 95% confidence interval, 1.48 to 3.06), and ceramide-22:0 (aHR per two-fold higher 0.59, 95% confidence interval, 0.44 to 0.79), with similar direction of associations for sphingomyelins. Twelve of 16 sphingolipids were associated with cardiovascular death, for example, ceramide-16:0 (aHR per two-fold higher 3.43, 95% confidence interval, 2.05 to 5.74). No sphingolipid was significantly associated with noncardiovascular death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a dedicated study of patients with kidney failure on hemodialysis, sphingolipids with long-chain fatty acids were strongly associated with greater risk of death, especially cardiovascular death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.0000000982","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:00:31Z","timestamp":1766163631000},"page":"1237-1247","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Association of Sphingolipids with All-Cause and Cardiovascular Death in Patients with Kidney Failure Treated with Maintenance Hemodialysis"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0484-4385","authenticated-orcid":false,"given":"Benjamin","family":"Lidgard","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-0243","authenticated-orcid":false,"given":"Andrew N.","family":"Hoofnagle","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-5111","authenticated-orcid":false,"given":"Leila R.","family":"Zelnick","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-7592","authenticated-orcid":false,"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-821X","authenticated-orcid":false,"given":"Paul","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5358-2345","authenticated-orcid":false,"given":"Amanda M.","family":"Fretts","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-175X","authenticated-orcid":false,"given":"David S.","family":"Siscovick","sequence":"additional","affiliation":[{"name":"New York Academy of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-3350","authenticated-orcid":false,"given":"Jason G.","family":"Umans","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-8628","authenticated-orcid":false,"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7038-1844","authenticated-orcid":false,"given":"Rozenn N.","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"1","key":"B1-20261014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2009.05.011","article-title":"Renal function, atherothrombosis extent, and outcomes in high-risk patients","volume":"158","author":"Dumaine","year":"2009","journal-title":"Am Heart J."},{"issue":"10","key":"B2-20261014","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/ATVBAHA.119.312705","article-title":"Atherosclerosis in chronic kidney disease: more, less, or just different?","volume":"39","author":"Valdivielso","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"3","key":"B3-20261014","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/sdi.12694","article-title":"Hemodialysis-induced cardiovascular disease","volume":"31","author":"Ahmadmehrabi","year":"2018","journal-title":"Semin Dial."},{"issue":"3","key":"B4-20261014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2006.08.042","article-title":"Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study","volume":"99","author":"Ahmed","year":"2007","journal-title":"Am J Cardiol."},{"issue":"8","key":"B5-20261014","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJMoa2304820","article-title":"Effect of hemodiafiltration or hemodialysis on mortality in kidney failure","volume":"389","author":"Blankestijn","year":"2023","journal-title":"N Engl J Med."},{"issue":"6","key":"B6-20261014","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int."},{"issue":"9784","key":"B7-20261014","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"issue":"3","key":"B8-20261014","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med."},{"issue":"6","key":"B9-20261014","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","article-title":"Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study","volume":"65","author":"Cheung","year":"2004","journal-title":"Kidney Int."},{"issue":"14","key":"B10-20261014","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med."},{"issue":"10","key":"B11-20261014","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1089\/ars.2017.7129","article-title":"Sphingolipids and redox signaling in renal regulation and chronic kidney diseases","volume":"28","author":"Bhat","year":"2018","journal-title":"Antioxid Redox Signal."},{"issue":"10","key":"B12-20261014","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","article-title":"Ceramides and other sphingolipids as drivers of cardiovascular disease","volume":"18","author":"Choi","year":"2021","journal-title":"Nat Rev Cardiol."},{"key":"B13-20261014","doi-asserted-by":"crossref","first-page":"616578","DOI":"10.3389\/fmed.2020.616578","article-title":"Sphingolipidomics in translational sepsis research-biomedical considerations and perspectives","volume":"7","author":"Claus","year":"2020","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"B14-20261014","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"1","key":"B15-20261014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2215\/CJN.13531119","article-title":"Lipids and cardiovascular risk with CKD","volume":"15","author":"Afshinnia","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B16-20261014","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1681\/ASN.2017030350","article-title":"Group tMKTCCI: impaired \u03b2-oxidation and altered complex lipid fatty acid partitioning with advancing CKD","volume":"29","author":"Afshinnia","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B17-20261014","doi-asserted-by":"crossref","first-page":"104765","DOI":"10.1016\/j.ebiom.2023.104765","article-title":"Evaluation of plasma sphingolipids as mediators of the relationship between kidney disease and cardiovascular events","volume":"95","author":"Lidgard","year":"2023","journal-title":"eBioMedicine."},{"issue":"3","key":"B18-20261014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/clinchem\/hvac216","article-title":"High-density lipoprotein lipidomics in chronic kidney disease","volume":"69","author":"Lidgard","year":"2023","journal-title":"Clin Chem."},{"issue":"10","key":"B19-20261014","doi-asserted-by":"crossref","first-page":"100708","DOI":"10.1016\/j.xkme.2023.100708","article-title":"High-density lipoprotein lipidomics and mortality in CKD","volume":"5","author":"Lidgard","year":"2023","journal-title":"Kidney Med."},{"issue":"1","key":"B20-20261014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2012.08.041","article-title":"Sphingolipids and atherosclerosis","volume":"226","author":"Hornemann","year":"2013","journal-title":"Atherosclerosis."},{"key":"B21-20261014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4614-0650-1_2","article-title":"Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy","volume":"721","author":"Jiang","year":"2011","journal-title":"Adv Exp Med Biol."},{"issue":"4","key":"B22-20261014","doi-asserted-by":"crossref","first-page":"e012853","DOI":"10.1161\/JAHA.119.012853","article-title":"Plasma ceramides and sphingomyelins in relation to atrial fibrillation risk: the Cardiovascular Health Study","volume":"9","author":"Jensen","year":"2020","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"B23-20261014","doi-asserted-by":"crossref","first-page":"e005708","DOI":"10.1161\/CIRCHEARTFAILURE.118.005708","article-title":"Plasma ceramides and sphingomyelins in relation to heart failure risk","volume":"12","author":"Lemaitre","year":"2019","journal-title":"Circ Heart Fail."},{"issue":"7","key":"B24-20261014","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.metabol.2009.10.026","article-title":"Endogenous red blood cell membrane fatty acids and sudden cardiac arrest","volume":"59","author":"Lemaitre","year":"2010","journal-title":"Metabolism."},{"issue":"2","key":"B25-20261014","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacl.2020.01.005","article-title":"Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies","volume":"14","author":"Mantovani","year":"2020","journal-title":"J Clin Lipidol."},{"issue":"1","key":"B26-20261014","doi-asserted-by":"crossref","first-page":"158821","DOI":"10.1016\/j.bbalip.2020.158821","article-title":"Consistent alteration of chain length-specific ceramides in human and mouse fibrotic kidneys","volume":"1866","author":"Eckes","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids."},{"issue":"1","key":"B27-20261014","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2011.11.001","article-title":"Chain length-specific properties of ceramides","volume":"51","author":"Gr\u00f6sch","year":"2012","journal-title":"Prog Lipid Res."},{"issue":"5","key":"B28-20261014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jb\/mvs105","article-title":"Very long-chain fatty acids: elongation, physiology and related disorders","volume":"152","author":"Kihara","year":"2012","journal-title":"J Biochem."},{"issue":"13","key":"B29-20261014","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1091\/mbc.e15-04-0229","article-title":"Very-long-chain fatty acid sphingomyelin in nuclear lipid microdomains of hepatocytes and hepatoma cells: can the exchange from C24:0 to C16:0 affect signal proteins and vitamin D receptor?","volume":"26","author":"Lazzarini","year":"2015","journal-title":"Mol Biol Cell."},{"key":"B30-20261014","doi-asserted-by":"crossref","first-page":"622692","DOI":"10.3389\/fendo.2020.622692","article-title":"Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease","volume":"11","author":"Nicholson","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B31-20261014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fendo.2020.00483","article-title":"Ceramide synthases are attractive drug targets for treating metabolic diseases","volume":"11","author":"Raichur","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"25","key":"B32-20261014","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N Engl J Med."},{"issue":"5","key":"B33-20261014","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0197-2456(00)00062-3","article-title":"Design and statistical issues of the Hemodialysis (HEMO) Study","volume":"21","author":"Greene","year":"2000","journal-title":"Control Clin Trials."},{"issue":"12","key":"B34-20261014","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/clinchem\/hvab182","article-title":"Circulating ceramides and sphingomyelins and risk of mortality: the Cardiovascular Health Study","volume":"67","author":"Fretts","year":"2021","journal-title":"Clin Chem."},{"issue":"8","key":"B35-20261014","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/db17-1449","article-title":"Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the Strong Heart Family Study","volume":"67","author":"Lemaitre","year":"2018","journal-title":"Diabetes."},{"issue":"6633","key":"B36-20261014","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/42408","article-title":"Functional rafts in cell membranes","volume":"387","author":"Simons","year":"1997","journal-title":"Nature."},{"issue":"1","key":"B37-20261014","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1038\/s41467-019-10711-1","article-title":"The role of PS 18:0\/18:1 in membrane function","volume":"10","author":"Skotland","year":"2019","journal-title":"Nat Commun."},{"issue":"1","key":"B38-20261014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12933-022-01596-4","article-title":"Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study","volume":"21","author":"Jensen","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"B40-20261014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate - a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Stat Methodol."},{"issue":"3","key":"B41-20261014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A direct approach to false discovery rates","volume":"64","author":"Storey","year":"2002","journal-title":"J R Stat Soc Ser B: Stat Methodol."},{"issue":"6","key":"B42-20261014","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1214\/aos\/1074290335","article-title":"The positive false discovery rate: a Bayesian interpretation and the q-value","volume":"31","author":"Storey","year":"2003","journal-title":"Ann Stat."},{"issue":"3","key":"B43-20261014","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1536867X0400400301","article-title":"Multiple imputation of missing values","volume":"4","author":"Royston","year":"2004","journal-title":"The Stata J Promoting Commun Stat Stata."},{"issue":"1","key":"B45-20261014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096228029900800102","article-title":"Multiple imputation: a primer","volume":"8","author":"Schafer","year":"1999","journal-title":"Stat Methods Med Res."},{"issue":"1","key":"B46-20261014","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.diabet.2020.03.003","article-title":"Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease","volume":"47","author":"Mantovani","year":"2021","journal-title":"Diabetes Metab."},{"issue":"5898","key":"B47-20261014","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.1158111","article-title":"Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans","volume":"322","author":"Deng","year":"2008","journal-title":"Science."},{"issue":"1","key":"B48-20261014","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1152\/ajpregu.00416.2005","article-title":"Physiological and pathophysiological aspects of ceramide","volume":"290","author":"Gulbins","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"3","key":"B49-20261014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.bmb.a011629","article-title":"Ceramide signaling in apoptosis","volume":"53","author":"Haimovitz-Friedman","year":"1997","journal-title":"Br Med Bull."},{"issue":"16","key":"B50-20261014","doi-asserted-by":"crossref","first-page":"11818","DOI":"10.1074\/jbc.M109.078121","article-title":"The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis","volume":"285","author":"Siskind","year":"2010","journal-title":"J Biol Chem."},{"issue":"7","key":"B51-20261014","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1172\/JCI10947","article-title":"A novel mouse model of lipotoxic cardiomyopathy","volume":"107","author":"Chiu","year":"2001","journal-title":"J Clin Invest."},{"issue":"1","key":"B52-20261014","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/mol.115.100222","article-title":"Bitopic sphingosine 1-phosphate receptor 3 (S1P3) antagonist rescue from complete heart block: pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction","volume":"89","author":"Sanna","year":"2016","journal-title":"Mol Pharmacol."},{"issue":"5","key":"B53-20261014","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cmet.2014.10.017","article-title":"C16:0-ceramide signals insulin resistance","volume":"20","author":"Hla","year":"2014","journal-title":"Cell Metab."},{"key":"B54-20261014","doi-asserted-by":"crossref","first-page":"e032536","DOI":"10.1161\/JAHA.123.032536","article-title":"Circulating sphingolipids and all-cause mortality: the strong heart family study","volume":"13","author":"Fretts","year":"2024","journal-title":"J Am Heart Assoc."},{"key":"B55-20261014","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1038\/s41467-018-05613-7","article-title":"A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism","volume":"9","author":"Turner","year":"2018","journal-title":"Nat Commun."},{"issue":"4","key":"B56-20261014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41574-020-0320-5","article-title":"The role of ceramides in metabolic disorders: when size and localization matters","volume":"16","author":"Turpin-Nolan","year":"2020","journal-title":"Nat Rev Endocrinol."},{"key":"B57-20261014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.amjcard.2020.04.052","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 inhibitors on plasma ceramide levels","volume":"128","author":"Ye","year":"2020","journal-title":"Am J Cardiol."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:00:39Z","timestamp":1791993639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000982","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2025-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}